mTor: Regulating Metabolic Disease, Cancer, and Aging

#mtor #kinesiology #aging This scientific review explores the mammalian target of rapamycin (mTOR) signaling pathway as a central regulator of biological aging and age-related pathology. The authors explain how overactive mTOR activity accelerates decline by inhibiting autophagy and promoting cellular senescence, protein synthesis errors, and mitochondrial dysfunction. By analyzing various model organisms, the text demonstrates that suppressing this pathway can potentially extend longevity and health span. The source evaluates pharmaceutical interventions, such as rapamycin and its analogs, alongside natural bioactive compounds like curcumin and resveratrol that target these mechanisms. While these inhibitors show promise in treating cancer, neurodegeneration, and metabolic disorders, the authors emphasize the need for refined dosing to mitigate significant side effects. Ultimately, the research positions the modulation of mTOR as a primary strategy for developing future anti-aging therapeutics. References Raghuvanshi, K., Raghuvanshi, D., Kumar, D., Nepovimova, E., Valko, M., Kuca, K., & Verma, R. (2025). Exploring the role of mTOR pathway in aging and age-related disorders. EXCLI journal, 24, 992–1015. https://doi.org/10.17179/excli2025-8384 Saxton, R. A., & Sabatini, D. M. (2017). mTOR Signaling in Growth, Metabolism, and Disease. Cell, 168(6), 960–976. https://doi.org/10.1016/j.cell.2017.02.004 #mtor #hgh #growthhormone #research #metabolism